PL4117784T3 - Związki stanowiące modulator gpr52 - Google Patents

Związki stanowiące modulator gpr52

Info

Publication number
PL4117784T3
PL4117784T3 PL21713103.6T PL21713103T PL4117784T3 PL 4117784 T3 PL4117784 T3 PL 4117784T3 PL 21713103 T PL21713103 T PL 21713103T PL 4117784 T3 PL4117784 T3 PL 4117784T3
Authority
PL
Poland
Prior art keywords
gpr52
modulator compounds
modulator
compounds
gpr52 modulator
Prior art date
Application number
PL21713103.6T
Other languages
English (en)
Inventor
Sarah Joanne BUCKNELL
Stephen Paul Watson
Michael Alistair O'brien
Original Assignee
Nxera Pharma Uk Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nxera Pharma Uk Limited filed Critical Nxera Pharma Uk Limited
Publication of PL4117784T3 publication Critical patent/PL4117784T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Optical Modulation, Optical Deflection, Nonlinear Optics, Optical Demodulation, Optical Logic Elements (AREA)
  • Amplifiers (AREA)
PL21713103.6T 2020-03-13 2021-03-15 Związki stanowiące modulator gpr52 PL4117784T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2003668.7A GB202003668D0 (en) 2020-03-13 2020-03-13 GPR52 Modulator compounds
PCT/GB2021/050638 WO2021181122A1 (en) 2020-03-13 2021-03-15 Gpr52 modulator compounds

Publications (1)

Publication Number Publication Date
PL4117784T3 true PL4117784T3 (pl) 2025-01-13

Family

ID=70453676

Family Applications (1)

Application Number Title Priority Date Filing Date
PL21713103.6T PL4117784T3 (pl) 2020-03-13 2021-03-15 Związki stanowiące modulator gpr52

Country Status (23)

Country Link
US (1) US20240254101A1 (pl)
EP (1) EP4117784B1 (pl)
JP (1) JP7492597B2 (pl)
KR (1) KR20220152296A (pl)
CN (1) CN115515681B (pl)
AU (1) AU2021235257A1 (pl)
BR (1) BR112022018287A2 (pl)
CA (1) CA3175429A1 (pl)
DK (1) DK4117784T3 (pl)
ES (1) ES2992600T3 (pl)
FI (1) FI4117784T3 (pl)
GB (1) GB202003668D0 (pl)
HR (1) HRP20241375T1 (pl)
HU (1) HUE068758T2 (pl)
IL (1) IL296413B2 (pl)
LT (1) LT4117784T (pl)
MX (1) MX2022011333A (pl)
PL (1) PL4117784T3 (pl)
PT (1) PT4117784T (pl)
RS (1) RS66063B1 (pl)
SI (1) SI4117784T1 (pl)
SM (1) SMT202400402T1 (pl)
WO (1) WO2021181122A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4139284A1 (en) 2020-04-22 2023-03-01 Neurocrine Biosciences, Inc. Gpr52 modulators and methods of use
US20240208907A1 (en) * 2021-04-26 2024-06-27 Neurocrine Biosciences, Inc. Gpr52 modulators and methods of use
GB202113186D0 (en) 2021-09-15 2021-10-27 Heptares Therapeutics Ltd GPR52 Modulator compounds
AR130864A1 (es) * 2022-10-26 2025-01-29 Neurocrine Biosciences Inc Compuestos y composiciones como moduladores de gpr52
WO2024091541A1 (en) * 2022-10-26 2024-05-02 Neurocrine Biosciences, Inc. Compounds and compositions as gpr52 modulators
TW202425979A (zh) * 2022-10-26 2024-07-01 美商紐羅克里生物科學有限公司 作為gpr52調節劑之化合物及組合物
WO2025252061A1 (zh) * 2024-06-04 2025-12-11 海思科医药集团股份有限公司 一种gpr52激动剂及其在医药上的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005037797A1 (en) * 2003-10-21 2005-04-28 Pharmacia Corporation Substituted pyrazole urea compounds for the treatment of inflammation
US20110009421A1 (en) * 2008-02-27 2011-01-13 Takeda Pharmaceutical Company Limited Compound having 6-membered aromatic ring
WO2011078360A1 (ja) * 2009-12-24 2011-06-30 武田薬品工業株式会社 アミド化合物
EP2530078A1 (en) * 2010-01-27 2012-12-05 Takeda Pharmaceutical Company Limited Thiazole derivative
CN108174603B (zh) * 2015-04-29 2021-07-02 阿芮纳制药有限公司 作为gpr52调节剂的1-杂芳基-二氢吲哚-4-甲酰胺
EP3681883B1 (en) 2017-09-13 2024-02-21 Novartis AG Diphenyl derivatives and uses thereof

Also Published As

Publication number Publication date
RS66063B1 (sr) 2024-11-29
WO2021181122A1 (en) 2021-09-16
GB202003668D0 (en) 2020-04-29
KR20220152296A (ko) 2022-11-15
IL296413A (en) 2022-11-01
LT4117784T (lt) 2024-10-25
DK4117784T3 (da) 2024-10-14
CA3175429A1 (en) 2021-09-16
SMT202400402T1 (it) 2024-11-15
EP4117784A1 (en) 2023-01-18
IL296413B1 (en) 2025-11-01
AU2021235257A1 (en) 2022-10-06
PT4117784T (pt) 2024-10-07
IL296413B2 (en) 2026-03-01
HRP20241375T1 (hr) 2024-12-20
CN115515681A (zh) 2022-12-23
EP4117784B1 (en) 2024-08-28
FI4117784T3 (fi) 2024-10-10
BR112022018287A2 (pt) 2022-11-22
MX2022011333A (es) 2022-12-08
JP2023519666A (ja) 2023-05-12
CN115515681B (zh) 2024-09-03
JP7492597B2 (ja) 2024-05-29
HUE068758T2 (hu) 2025-01-28
US20240254101A1 (en) 2024-08-01
SI4117784T1 (sl) 2025-03-31
ES2992600T3 (en) 2024-12-16

Similar Documents

Publication Publication Date Title
DK4165024T3 (da) Cyclobutyldihydroquinolinsulfonamid-forbindelser
EP4129997A4 (en) Octahydropyrazinodiazanaphthyridine dione compounds
IL292753A (en) Compounds
DK4271672T3 (da) Carboxy-benzimidazol glp-1r-modulerende forbindelser
IL286833A (en) Compositions containing brazzein
IL288174A (en) Pyrrolidine compounds
PL4271674T6 (pl) Karboksybenzimidazolowe związki modulujące glp-1r
EP4164748C0 (en) CYCLOPROPYL-DIHYDROQUINOLINE SULFONAMIDE COMPOUNDS
EP4165032C0 (en) HETEROALKYL DIHYDROQUINOLINE SULFONAMIDE COMPOUNDS
IL310528A (en) Pyrazolopyridinone compounds
SMT202400402T1 (it) Composti modulatori gpr52
IL309378A (en) Diacylglyercol kinase modulating compounds
EP4149556C0 (en) PEG LIPIDOIDS COMPOUNDS
EP4293025C0 (en) COMPOSED WITH 4-AMINOQUINAZOLINE
DK4320112T3 (da) Pyridinylsubstituerede oxoisoindolinforbindelser
IL286902A (en) Pyrrole compounds
EP4143199C0 (en) NUCLEOTIDE PROMEDICINAL COMPOUNDS
EP3945361C0 (en) ACOUSTO-OPTICAL MODULATOR
EP4400902A4 (en) ELECTRO-OPTIC MODULATOR
DK4168401T3 (da) Sulfonamidforbindelser
EP4025957C0 (en) ELECTRO-OPTIC MODULATOR
EP3779540A4 (en) Optical modulator
DK4401833T3 (da) Gpr52-modulatorforbindelser
EP4289123C0 (de) Containervermittelte anwendungskonfiguration
IL313590A (en) Compounds